Cargando…

Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors

Ubiquitination is extensively involved in critical signaling pathways through monitoring protein stability, subcellular localization, and activity. Dysregulation of this process results in severe diseases including malignant cancers. To develop drugs targeting ubiquitination-related factors is a hot...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qianqian, Zhang, Weiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737479/
https://www.ncbi.nlm.nih.gov/pubmed/36499442
http://dx.doi.org/10.3390/ijms232315104
_version_ 1784847299481960448
author Li, Qianqian
Zhang, Weiwei
author_facet Li, Qianqian
Zhang, Weiwei
author_sort Li, Qianqian
collection PubMed
description Ubiquitination is extensively involved in critical signaling pathways through monitoring protein stability, subcellular localization, and activity. Dysregulation of this process results in severe diseases including malignant cancers. To develop drugs targeting ubiquitination-related factors is a hotspot in research to realize better therapy of human diseases. Ubiquitination comprises three successive reactions mediated by Ub-activating enzyme E1, Ub-conjugating enzyme E2, and Ub ligase E3. As expected, multiple ubiquitination enzymes have been highlighted as targets for anticancer drug development due to their dominant effect on tumorigenesis and cancer progression. In this review, we discuss recent progresses in anticancer drug development targeting enzymatic machinery components.
format Online
Article
Text
id pubmed-9737479
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97374792022-12-11 Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors Li, Qianqian Zhang, Weiwei Int J Mol Sci Review Ubiquitination is extensively involved in critical signaling pathways through monitoring protein stability, subcellular localization, and activity. Dysregulation of this process results in severe diseases including malignant cancers. To develop drugs targeting ubiquitination-related factors is a hotspot in research to realize better therapy of human diseases. Ubiquitination comprises three successive reactions mediated by Ub-activating enzyme E1, Ub-conjugating enzyme E2, and Ub ligase E3. As expected, multiple ubiquitination enzymes have been highlighted as targets for anticancer drug development due to their dominant effect on tumorigenesis and cancer progression. In this review, we discuss recent progresses in anticancer drug development targeting enzymatic machinery components. MDPI 2022-12-01 /pmc/articles/PMC9737479/ /pubmed/36499442 http://dx.doi.org/10.3390/ijms232315104 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Li, Qianqian
Zhang, Weiwei
Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors
title Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors
title_full Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors
title_fullStr Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors
title_full_unstemmed Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors
title_short Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors
title_sort progress in anticancer drug development targeting ubiquitination-related factors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737479/
https://www.ncbi.nlm.nih.gov/pubmed/36499442
http://dx.doi.org/10.3390/ijms232315104
work_keys_str_mv AT liqianqian progressinanticancerdrugdevelopmenttargetingubiquitinationrelatedfactors
AT zhangweiwei progressinanticancerdrugdevelopmenttargetingubiquitinationrelatedfactors